-
Managing cancer following the World Trade Center disaster Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-11 Rachel Zeig-Owens, David J. Prezant
The World Trade Center (WTC) disaster exposed individuals to carcinogens, leading to elevated cancer rates. Responders who received care through the WTC Health Program have higher survival rates. Twenty-three years post-disaster, we summarize cancer incidence and outcome studies in this population and highlight the importance of a dedicated health programme response.
-
Creating a dietary vulnerability Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-10 Daniela Senft
In a recent Nature paper, Ruggero and colleagues found that fasting and ketogenic diets induce metabolic rewiring through a translational mechanism involving MNK-mediated phosphorylation of eIF4E, which enhances ketogenesis. This process creates a metabolic vulnerability in pancreatic cancer that could be therapeutically exploited.
-
The evolutionary theory of cancer: challenges and potential solutions Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-10 Lucie Laplane, Carlo C. Maley
-
CAF-induced physical constraints controlling T cell state and localization in solid tumours Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-09 Ludovica Arpinati, Giulia Carradori, Ruth Scherz-Shouval
-
Overcoming heterogeneity with 3D whole-tumour sampling Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-06 Radhika Mathur
In this Tools of the Trade article, Radhika Mathur describes the development of a novel 3D whole-tumour sampling approach for glioblastoma, which can be used to elucidate tumour heterogeneity.
-
Intercepting gastric cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-05 Anna Dart
Pan et al. performed a large-scale, cluster-randomized controlled trial to assess whether eradicating Helicobacter pylori in asymptomatic individuals would be beneficial in preventing gastric cancer.
-
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-02 Mariangela Russo, Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K. Rehman, Elena Sancho, Alberto Sogari, Tzen S. Toh, Nathalie Q. Balaban, Eduard Batlle, Rene Bernards, Mathew J. Garnett, Matthew Hangauer, Eleonora Leucci, Jean-Christophe Marine, Catherine A. O’Brien, Yaara Oren, E. Elizabeth Patton, Caroline Robert, Susan M. Rosenberg, Shensi Shen, Alberto Bardelli
-
Targeting the tumour vasculature: from vessel destruction to promotion Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-29 Sophie Guelfi, Kairbaan Hodivala-Dilke, Gabriele Bergers
-
Author Correction: Integrative medicine in oncology: redefining the standard of care. Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-29 Gabriel Lopez,Santhosshi Narayanan,Lorenzo Cohen
-
Limiting bias in AI models for improved and equitable cancer care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-27 Marzyeh Ghassemi, Alexander Gusev
Cancer screening, diagnosis and care stand to benefit greatly from advances in artificial intelligence (AI). Researchers, developers and deployers must ensure that applications of AI avoid known racial and gender biases to advance health care for all. Cancer screening, diagnosis and care can benefit greatly from advances in artificial intelligence (AI). In this Comment, Ghassemi and Gusev discuss how
-
Thelpers? More like Ttroublemakers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-19 Gabrielle Brewer
Inflammation is well established as a risk factor for cancer development in the gut. In this study, Fesneau et al. identify a specific immune cell population, derived from T helper 17 (TH17) cells, that can initiate intestinal cancer.
-
Integrative medicine in oncology: redefining the standard of care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-16 Gabriel Lopez, Santhosshi Narayanan, Lorenzo Cohen
Integrative medicine incorporated alongside cancer care, referred to as integrative oncology, is an evidence-informed field with established clinical guidelines. Although integrative oncology improves patient outcomes, it is inconsistently provided to patients. To align with best practices, it is necessary to increase awareness of integrative oncology, improve access to treatments, and provide consistent
-
Tracing the evolutionary history of breast cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-14 Jiwon Koh, Seock-Ah Im
In this Journal Club, Koh and Im discuss a study demonstrating the unique evolutionary trajectory of breast cancers harbouring the common driver alteration der(1;16).
-
Tertiary lymphoid structures in anticancer immunity Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-08 Jean-Luc Teillaud, Ana Houel, Marylou Panouillot, Clémence Riffard, Marie-Caroline Dieu-Nosjean
-
Lactate promotes DNA repair Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-05 Daniela Senft
In a recent study published in Nature, lactate has been identified as a key player in enhancing DNA repair mechanisms in gastric cancer by promoting lactylation of DNA repair proteins, leading to chemotherapy resistance.
-
Publisher Correction: Structural variations in cancer and the 3D genome. Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-05 Frank Dubois,Nikos Sidiropoulos,Joachim Weischenfeldt,Rameen Beroukhim
-
Shared immunosuppressive mechanism between pregnancy and cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-01 Linda Gummlich
Pregnancy involves immune system suppression to protect the fetus, making it a valuable model for understanding cancer immune tolerance. Recently in Cell, Yu et al. identified B7-H4 as a common immune tolerance checkpoint in both tumours and the placenta.
-
Rational combination of cancer therapies with PD1 axis blockade Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-30
This poster explores rational combinations of immune checkpoint blockade of the PD1–PDL1 interaction with other therapies aimed at targeting effector T cells, innate immune and regulatory cells, the tumour microenvironment and cancer cells.
-
Circular RNA in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-29 Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn
-
Pre-empting drug resistance Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-24 Anna Dart
Leighow et al. develop a strategy called the dual-switch selection gene drive platform, which enables the evolutionary dynamics of acquired resistance to be manipulated for therapeutic ends.
-
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-24 Nils Wellhausen, Joanne Baek, Saar I. Gill, Carl H. June
-
The impact of sex on metastasis Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-22 Yingsheng Zhang, Xue Li
-
In-depth organoid profiling of pancreatic cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-09 Ju Eun Maeng, Ja-Lok Ku
In this Journal Club, Maeng and Ku discuss a study demonstrating that profiling drug responses in patient-derived organoids can identify responders to various therapies.
-
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-09 Amir Z. Munir, Alan Gutierrez, Juan Qin, Andrew H. Lichtman, Javid J. Moslehi
-
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-08 Roel Polak, Elisa T. Zhang, Calvin J. Kuo
-
ASS1: Guardian of the genome Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-05 Gabrielle Brewer
Lim et al. show that ASS1, silenced in many cancer types, is a metabolic checkpoint that, following DNA damage, halts cell cycle progression by restricting nucleotide synthesis and p53-related gene transcription.
-
Towards targeting the breast cancer immune microenvironment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-05 Michael A. Harris, Peter Savas, Balaji Virassamy, Megan M. R. O’Malley, Jasmine Kay, Scott N. Mueller, Laura K. Mackay, Roberto Salgado, Sherene Loi
-
Carcinogenesis at single-cell resolution Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-04 Daniela Senft
In this study, Allan Balmain and colleagues used a mouse model to monitor stem cell networks at single-cell resolution during skin carcinogenesis, revealing two cancer stem cell states, rapid cycling and plasticity, between which cells can transition to drive tumour initiation, progression and therapy resistance.
-
Preprints as tools to advance careers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-02 Samantha Hindle, Richard Sever
-
Oncologists must act to manage cancer detected through prenatal screening Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-01 Amy E. Turriff, Diana W. Bianchi
-
Author Correction: Developmental origins shape the paediatric cancer genome. Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-01 Xiaolong Chen,Wentao Yang,Charles W M Roberts,Jinghui Zhang
-
The rhythm of the night Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-25 Gabrielle Brewer
Patient progression and response to immunotherapy are directly influenced by the presence and quality of tumour-infiltrating leukocytes (TILs). In a recent Cell publication, Wang, Zeng et al. demonstrate the functional role of circadian rhythms in altering TIL functionality and quantity, highlighting the therapeutic potential of leveraging this understanding.
-
The road less travelled Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-21
In our Roadmap articles, we ask authors to provide a sense of direction to a field, to encourage new lines of thinking and experimentation, as well as opportunities for collaboration. This month, Nature Reviews Cancer launches Roadmap articles, in which we ask authors to provide a sense of direction to a field to encourage new lines of thinking and experimentation, as well as opportunities for collaboration
-
Why do patients with cancer die? Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-19 Adrienne Boire, Katy Burke, Thomas R. Cox, Theresa Guise, Mariam Jamal-Hanjani, Tobias Janowitz, Rosandra Kaplan, Rebecca Lee, Charles Swanton, Matthew G. Vander Heiden, Erik Sahai
-
Exploiting temporal aspects of cancer immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-17 Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V. Long, Willem Joost Lesterhuis
-
The importance of 3D fibre architecture in cancer and implications for biomaterial model design Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-17 J. C. Ashworth, T. R. Cox
-
The path to leptomeningeal metastasis Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-13 Jan Remsik, Adrienne Boire
-
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-12 Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna Parikh, Genevieve M. Boland
-
Charting spatially resolved cell states with CytoSPACE Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-10 Erin L. Brown
In this Tools of the Trade article, Erin Brown describes the development of CytoSPACE, a computational tool that aligns single-cell transcriptomes and spatial transcriptomic data, and highlights its use in identifying spatially resolved cell states in the tumour microenvironment.
-
Eliminating false positives Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-10 Daniela Senft
To establish microbiome-based screening for colorectal cancer, a study published in Nature Medicine tackled two key challenges: utilizing quantitative microbiome profiling and identifying covariates that might obscure the microbiota–colorectal cancer interactions.
-
Bone voyage: immune crosstalk sets sail Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-04 Gabrielle Brewer
Monteran et al. identified key interactions between granulocytes and T cells that promote an immunosuppressive bone microenvironment, enabling breast cancer metastasis.
-
No mutation, tumour initiation Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-29 Daniela Senft
Parreno et al. provide evidence for epigenetically initiated cancers in Drosophila and show that cancer develops after transient loss of Polycomb group proteins in the absence of recurrent mutations.
-
Liquid biopsies for Hodgkin lymphoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-23 Sojung Lim, Yoon Kyung Jeon
In this Journal Club, Lim and Jeon discuss a recent study demonstrating the utility of noninvasive genomic profiling for subtyping Hodgkin lymphomas.
-
Taking a detour Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Anna Dart
Kong et al. have now shown that Knudson’s two-hit hypothesis can be circumvented through the actions of the glycolytic metabolite methylglyoxal, which transiently inactivates the tumour-suppressive functions of BRCA2 leading to episodic mutagenesis and cancer genome evolution.
-
Finding the truth in science Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Elisabeth M. Bik
In a ‘publish or perish’ culture, some scientists may resort to questionable research practices or even fraud. Scientific paper mills and artificial intelligence increasingly threaten the pursuit of truth in science. Structural changes, including heightened scrutiny of papers and authorship and better funding, are needed to ensure scientific integrity.
-
A guide to artificial intelligence for cancer researchers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Raquel Perez-Lopez, Narmin Ghaffari Laleh, Faisal Mahmood, Jakob Nikolas Kather
-
Cancer therapy with antibodies Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-13 Suman Paul, Maximilian F. Konig, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M. Wright, Sandra B. Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
-
Right ON target: a new RAS-GTP inhibitor Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-10 Daniela Senft
Two studies published concurrently in Nature report the development and preclinical activity of RMC-7977, a multi-selective inhibitor targeting the active, GTP-bound form of RAS.
-
AACR 2024 Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-08 Gabrielle Brewer
The annual American Association for Cancer Research (AACR) meeting provides a platform for scientists, clinicians and other stakeholders to share the latest advances in cancer science and medicine. Here, we outline some highlights of the 2024 meeting.
-
A MEGA RNA-editing tool Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-07 Victor Tieu
In this Tools of the Trade article, Victor Tieu describes the development of MEGA, a platform that exploits the RNA-targeting capability of CRISPR–Cas13d and demonstrates its use to improve the anti-tumour activity of CAR T cells.
-
Histological transformation to small-cell carcinoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-02 Songji Oh, Tae Min Kim
In this Journal Club, Oh and Kim discuss a study demonstrating the mechanisms underlying histological transformation of lung adenocarcinoma to neuroendocrine small-cell lung cancer.
-
Developmental origins shape the paediatric cancer genome Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-02 Xiaolong Chen, Wentao Yang, Charles W. M. Roberts, Jinghui Zhang
-
Too much of a good thing Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-30 Anna Dart
Dias et al. have shown that intentional further activation of oncogenic signalling rather than its inhibition represents an alternative strategy leading to colorectal cancer cell death with tumour suppressive acquired resistance.
-
Using the tumour microenvironment to improve therapy efficacy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-26 Zuzana Tatarova
Targeted anticancer agents and chemotherapies exploit vulnerabilities intrinsic to cancer cells. However, evidence suggests the local tumour microenvironment (TME) can affect tumour behaviour to enhance or inhibit tumour growth. Drugs that target tumour cell vulnerabilities have been shown to also affect the TME. Understanding these effects will enable the development of drug combinations that directly
-
Investigating immune cells across time in vivo Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-22 Daniel Kirschenbaum
In this Tools of the Trade article, Daniel Kirschenbaum describes the development of Zman-seq and its utility for capturing dynamic changes in cellular state within single-cell RNA sequencing data.
-
Guardrails for the use of generalist AI in cancer care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-16 Stephen Gilbert, Jakob Nikolas Kather
-
Combinatorial strategies to target RAS-driven cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-16 Naiara Perurena, Lisa Situ, Karen Cichowski
-
Programming immune escape Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-12 Daniela Senft
In a recent study published in Nature, Goto et al. explore mechanisms of immune evasion in early colorectal cancers and adenomas and identify SOX17 to be crucial for immune escape through suppression of interferon-γ signalling.
-
NET-working under stress Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-12 Gabrielle Brewer
In this recent study, He et al. establish that chronic stress promotes metastasis through stress-induced formation of neutrophil extracellular traps (NETs).
-
Lymphatic vessels in the age of cancer immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-11 Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund